Compare Dollar Tree, Inc. (DLTR) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar Tree, Inc. vs Johnson & Johnson — how do they compare? Dollar Tree, Inc. trades at $117.94 (market cap $22.26B), while Johnson & Johnson trades at $260.85 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 27.8× Dollar Tree, Inc.'s market cap, and Johnson & Johnson pays a 2.09% dividend while Dollar Tree, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dollar Tree, Inc. for 58 Days and Johnson & Johnson for 129 Days on average.
| DLTR | JNJ | |
|---|---|---|
Market Cap | $22.26B | $618.09B |
Volume | 2,317,428 | 6,050,983 |
Sector | Consumer Staples | Health |
52-Week High | $141.21 | $278.43 |
52-Week Low | $86.80 | $186.00 |
Typical Hold Time | 58 Days | 129 Days |
Enterprise Value | $28.87B | $646.37B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar Tree (DLTR) trades at $117.42, up 0.96% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust profitability with a 45.87% ROE and trades at a modest P/E of 14.54. Recent news highlights strategic initiatives and store expansions supporting growth, though margin risks from tariffs and reinvestment remain a focus.
The outlook is positive with a consensus price target of $139.33, implying 18.7% upside, but investors face risks from volatile margins, high debt levels, and competitive pressures. Earnings improvement and institutional buying provide support, yet the stock's recent decline of 17.9% over the past month underscores near-term challenges.
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dollar Tree, Inc.
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
